All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021
Details:
The Phase I trial, which will enrol 30 healthy volunteers aged 18–40, will investigate the level of immune system responses generated by the ChAdOx1 nCoV-19 using this delivery technique, as well as monitoring safety and for any adverse reactions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Foralumab,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: NI-0401
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2021
Details:
The scientific approaches underlying this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses. Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVI-VAC
Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Codagenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Foralumab,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Trial arranged in collaboration with Harvard Medical School and Dr. Howard Weiner. A patent application was filed in July 2020 to protect the potential use of nasally administered Foralumab to treat COVID-19 either alone or in combination with other anti-viral drugs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZD7442
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $486.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 09, 2020
Details:
AstraZeneca plans to supply up to 100,000 doses of AZD7442 starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZD7442
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Notable abstracts include data from the first randomized controlled Phase 3 study of a PCSK9 inhibitor, Repatha, in pediatric patients with heterozygous familial hypercholesterolemia (HeFH), which will be presented as a late-breaking abstract in an oral presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-CO
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
